The  ||| S:0 E:4 ||| DT
matrix  ||| S:4 E:11 ||| JJ
metalloproteinase-7  ||| S:11 E:31 ||| NN
and  ||| S:31 E:35 ||| CC
pro-enzyme  ||| S:35 E:46 ||| JJ
of  ||| S:46 E:49 ||| IN
metalloproteinase-1  ||| S:49 E:69 ||| CD
as  ||| S:69 E:72 ||| IN
a  ||| S:72 E:74 ||| DT
potential  ||| S:74 E:84 ||| JJ
marker  ||| S:84 E:91 ||| NN
for  ||| S:91 E:95 ||| IN
patients  ||| S:95 E:104 ||| NNS
with  ||| S:104 E:109 ||| IN
rectal  ||| S:109 E:116 ||| JJ
cancer  ||| S:116 E:123 ||| NN
without  ||| S:123 E:131 ||| IN
distant  ||| S:131 E:139 ||| JJ
metastasis  ||| S:139 E:150 ||| NNS
The  ||| S:150 E:154 ||| DT
aim  ||| S:154 E:158 ||| NN
of  ||| S:158 E:161 ||| IN
this  ||| S:161 E:166 ||| DT
study  ||| S:166 E:172 ||| NN
was  ||| S:172 E:176 ||| VBD
the  ||| S:176 E:180 ||| DT
evaluation  ||| S:180 E:191 ||| NN
of  ||| S:191 E:194 ||| IN
clinical  ||| S:194 E:203 ||| JJ
usage  ||| S:203 E:209 ||| NN
of  ||| S:209 E:212 ||| IN
metalloproteinase  ||| S:212 E:230 ||| NNS
( ||| S:230 E:231 ||| -LRB-
MMP ||| S:231 E:234 ||| NNP
) ||| S:234 E:235 ||| -RRB-
:  ||| S:235 E:237 ||| :
proMMP-1 ||| S:237 E:245 ||| CD
,  ||| S:245 E:247 ||| ,
MMP-2 ||| S:247 E:252 ||| NNP
,  ||| S:252 E:254 ||| ,
MMP-7 ||| S:254 E:259 ||| NNP
,  ||| S:259 E:261 ||| ,
MMP-9 ||| S:261 E:266 ||| NNP
,  ||| S:266 E:268 ||| ,
tissue  ||| S:268 E:275 ||| NN
inhibitors  ||| S:275 E:286 ||| NN
of  ||| S:286 E:289 ||| IN
metalloproteinase  ||| S:289 E:307 ||| NNS
( ||| S:307 E:308 ||| -LRB-
TIMP ||| S:308 E:312 ||| NNP
) ||| S:312 E:313 ||| -RRB-
-1  ||| S:313 E:316 ||| NNP
and  ||| S:316 E:320 ||| CC
TIMP-2  ||| S:320 E:327 ||| CD
in  ||| S:327 E:330 ||| IN
serum  ||| S:330 E:336 ||| NN
of  ||| S:336 E:339 ||| IN
patients  ||| S:339 E:348 ||| NNS
with  ||| S:348 E:353 ||| IN
rectal  ||| S:353 E:360 ||| JJ
cancer ||| S:360 E:366 ||| NN
,  ||| S:366 E:368 ||| ,
as  ||| S:368 E:371 ||| RB
well  ||| S:371 E:376 ||| RB
as  ||| S:376 E:379 ||| IN
the  ||| S:379 E:383 ||| DT
selection  ||| S:383 E:393 ||| NN
of  ||| S:393 E:396 ||| IN
parameters  ||| S:396 E:407 ||| NNS
of  ||| S:407 E:410 ||| IN
the  ||| S:410 E:414 ||| DT
greatest  ||| S:414 E:423 ||| JJS
diagnostic  ||| S:423 E:434 ||| JJ
sensitivity  ||| S:434 E:446 ||| NN
and  ||| S:446 E:450 ||| CC
the  ||| S:450 E:454 ||| DT
determination  ||| S:454 E:468 ||| NN
of  ||| S:468 E:471 ||| IN
their  ||| S:471 E:477 ||| PRP$
relation  ||| S:477 E:486 ||| NN
with  ||| S:486 E:491 ||| IN
clinicopathological  ||| S:491 E:511 ||| JJ
features ||| S:511 E:519 ||| NNS
,  ||| S:519 E:521 ||| ,
what  ||| S:521 E:526 ||| WP
is  ||| S:526 E:529 ||| VBZ
more ||| S:529 E:533 ||| RBR
,  ||| S:533 E:535 ||| ,
the  ||| S:535 E:539 ||| DT
demonstration  ||| S:539 E:553 ||| NN
whether  ||| S:553 E:561 ||| IN
their  ||| S:561 E:567 ||| PRP$
concentrations  ||| S:567 E:582 ||| NNS
may  ||| S:582 E:586 ||| MD
have  ||| S:586 E:591 ||| VB
a  ||| S:591 E:593 ||| DT
prognostic  ||| S:593 E:604 ||| JJ
value  ||| S:604 E:610 ||| NN
in  ||| S:610 E:613 ||| IN
the  ||| S:613 E:617 ||| DT
assessment  ||| S:617 E:628 ||| NN
of  ||| S:628 E:631 ||| IN
disease-free  ||| S:631 E:644 ||| JJ
survival  ||| S:644 E:653 ||| NN
( ||| S:653 E:654 ||| -LRB-
DFS ||| S:654 E:657 ||| NNP
)  ||| S:657 E:659 ||| -RRB-
and  ||| S:659 E:663 ||| CC
overall  ||| S:663 E:671 ||| JJ
survival  ||| S:671 E:680 ||| NN
( ||| S:680 E:681 ||| -LRB-
OS ||| S:681 E:683 ||| NNP
) ||| S:683 E:684 ||| -RRB-
.  ||| S:684 E:686 ||| .
The  ||| S:686 E:690 ||| DT
study  ||| S:690 E:696 ||| NN
comprised  ||| S:696 E:706 ||| VBD
100  ||| S:706 E:710 ||| CD
patients  ||| S:710 E:719 ||| NNS
with  ||| S:719 E:724 ||| IN
rectal  ||| S:724 E:731 ||| JJ
cancer  ||| S:731 E:738 ||| NN
including  ||| S:738 E:748 ||| VBG
29  ||| S:748 E:751 ||| CD
women  ||| S:751 E:757 ||| NNS
and  ||| S:757 E:761 ||| CC
71  ||| S:761 E:764 ||| CD
men ||| S:764 E:767 ||| NNS
.  ||| S:767 E:769 ||| .
The  ||| S:769 E:773 ||| DT
tested  ||| S:773 E:780 ||| JJ
group  ||| S:780 E:786 ||| NN
was  ||| S:786 E:790 ||| VBD
comprised  ||| S:790 E:800 ||| VBN
of  ||| S:800 E:803 ||| IN
qualified  ||| S:803 E:813 ||| JJ
patients  ||| S:813 E:822 ||| NNS
without  ||| S:822 E:830 ||| IN
distant  ||| S:830 E:838 ||| JJ
metastasis  ||| S:838 E:849 ||| NNS
( ||| S:849 E:850 ||| -LRB-
M0 ||| S:850 E:852 ||| NNP
) ||| S:852 E:853 ||| -RRB-
.  ||| S:853 E:855 ||| .
It  ||| S:855 E:858 ||| PRP
was  ||| S:858 E:862 ||| VBD
demonstrated  ||| S:862 E:875 ||| VBN
that  ||| S:875 E:880 ||| IN
in  ||| S:880 E:883 ||| IN
patients  ||| S:883 E:892 ||| NNS
with  ||| S:892 E:897 ||| IN
rectal  ||| S:897 E:904 ||| JJ
cancer ||| S:904 E:910 ||| NN
,  ||| S:910 E:912 ||| ,
the  ||| S:912 E:916 ||| DT
concentrations  ||| S:916 E:931 ||| NNS
of  ||| S:931 E:934 ||| IN
MMP-9 ||| S:934 E:939 ||| NNP
,  ||| S:939 E:941 ||| ,
MMP-7 ||| S:941 E:946 ||| NNP
,  ||| S:946 E:948 ||| ,
and  ||| S:948 E:952 ||| CC
proMMP-1  ||| S:952 E:961 ||| CD
as  ||| S:961 E:964 ||| IN
well  ||| S:964 E:969 ||| RB
as  ||| S:969 E:972 ||| IN
TIMP-1  ||| S:972 E:979 ||| NNP
were  ||| S:979 E:984 ||| VBD
significantly  ||| S:984 E:998 ||| RB
higher  ||| S:998 E:1005 ||| JJR
in  ||| S:1005 E:1008 ||| IN
comparison  ||| S:1008 E:1019 ||| NN
to  ||| S:1019 E:1022 ||| TO
the  ||| S:1022 E:1026 ||| DT
reference  ||| S:1026 E:1036 ||| NN
group ||| S:1036 E:1041 ||| NN
.  ||| S:1041 E:1043 ||| .
On  ||| S:1043 E:1046 ||| IN
the  ||| S:1046 E:1050 ||| DT
basis  ||| S:1050 E:1056 ||| NN
of  ||| S:1056 E:1059 ||| IN
ROC  ||| S:1059 E:1063 ||| NNP
curves ||| S:1063 E:1069 ||| NN
,  ||| S:1069 E:1071 ||| ,
the  ||| S:1071 E:1075 ||| DT
greatest  ||| S:1075 E:1084 ||| JJS
diagnostic  ||| S:1084 E:1095 ||| JJ
sensitivity  ||| S:1095 E:1107 ||| NN
of  ||| S:1107 E:1110 ||| IN
MMP-9  ||| S:1110 E:1116 ||| NNP
was  ||| S:1116 E:1120 ||| VBD
demonstrated ||| S:1120 E:1132 ||| VBN
.  ||| S:1132 E:1134 ||| .
When  ||| S:1134 E:1139 ||| WRB
evaluating  ||| S:1139 E:1150 ||| VBG
the  ||| S:1150 E:1154 ||| DT
correlation  ||| S:1154 E:1166 ||| NN
of  ||| S:1166 E:1169 ||| IN
tested  ||| S:1169 E:1176 ||| JJ
parameters  ||| S:1176 E:1187 ||| NNS
with  ||| S:1187 E:1192 ||| IN
the  ||| S:1192 E:1196 ||| DT
size  ||| S:1196 E:1201 ||| NN
of  ||| S:1201 E:1204 ||| IN
the  ||| S:1204 E:1208 ||| DT
tumor  ||| S:1208 E:1214 ||| NN
( ||| S:1214 E:1215 ||| -LRB-
T1-T2  ||| S:1215 E:1221 ||| FW
vs  ||| S:1221 E:1224 ||| FW
T3-T4 ||| S:1224 E:1229 ||| FW
) ||| S:1229 E:1230 ||| -RRB-
,  ||| S:1230 E:1232 ||| ,
essential  ||| S:1232 E:1242 ||| JJ
differences  ||| S:1242 E:1254 ||| NNS
were  ||| S:1254 E:1259 ||| VBD
shown  ||| S:1259 E:1265 ||| VBN
for  ||| S:1265 E:1269 ||| IN
proMMP-1  ||| S:1269 E:1278 ||| CD
concentrations ||| S:1278 E:1292 ||| NNS
.  ||| S:1292 E:1294 ||| .
The  ||| S:1294 E:1298 ||| DT
highest  ||| S:1298 E:1306 ||| JJS
percentage  ||| S:1306 E:1317 ||| NN
of  ||| S:1317 E:1320 ||| IN
patients  ||| S:1320 E:1329 ||| NNS
with  ||| S:1329 E:1334 ||| IN
progression  ||| S:1334 E:1346 ||| NN
had  ||| S:1346 E:1350 ||| VBD
an  ||| S:1350 E:1353 ||| DT
increased  ||| S:1353 E:1363 ||| JJ
concentration  ||| S:1363 E:1377 ||| NN
of  ||| S:1377 E:1380 ||| IN
MMP-7  ||| S:1380 E:1386 ||| NNP
and  ||| S:1386 E:1390 ||| CC
TIMP-1 ||| S:1390 E:1396 ||| NNP
.  ||| S:1396 E:1398 ||| .
During  ||| S:1398 E:1405 ||| IN
a  ||| S:1405 E:1407 ||| DT
5-year  ||| S:1407 E:1414 ||| NNP
follow-up ||| S:1414 E:1423 ||| NNP
,  ||| S:1423 E:1425 ||| ,
univariate  ||| S:1425 E:1436 ||| JJ
log-rank  ||| S:1436 E:1445 ||| JJ
analysis  ||| S:1445 E:1454 ||| NN
had  ||| S:1454 E:1458 ||| VBD
shown  ||| S:1458 E:1464 ||| VBN
an  ||| S:1464 E:1467 ||| DT
essential  ||| S:1467 E:1477 ||| JJ
dependence  ||| S:1477 E:1488 ||| NN
between  ||| S:1488 E:1496 ||| IN
the  ||| S:1496 E:1500 ||| DT
concentration  ||| S:1500 E:1514 ||| NN
of  ||| S:1514 E:1517 ||| IN
MMP-7  ||| S:1517 E:1523 ||| CD
in  ||| S:1523 E:1526 ||| IN
men  ||| S:1526 E:1530 ||| NNS
and  ||| S:1530 E:1534 ||| CC
DSF  ||| S:1534 E:1538 ||| NNP
which  ||| S:1538 E:1544 ||| WDT
was  ||| S:1544 E:1548 ||| VBD
confirmed  ||| S:1548 E:1558 ||| VBN
in  ||| S:1558 E:1561 ||| IN
Cox  ||| S:1561 E:1565 ||| NNP
multivariate  ||| S:1565 E:1578 ||| JJ
analysis ||| S:1578 E:1586 ||| NN
.  ||| S:1586 E:1588 ||| .
It  ||| S:1588 E:1591 ||| PRP
was  ||| S:1591 E:1595 ||| VBD
demonstrated  ||| S:1595 E:1608 ||| VBN
that  ||| S:1608 E:1613 ||| IN
the  ||| S:1613 E:1617 ||| DT
pretreatment  ||| S:1617 E:1630 ||| JJ
concentration  ||| S:1630 E:1644 ||| NN
of  ||| S:1644 E:1647 ||| IN
proMMP-1  ||| S:1647 E:1656 ||| NNP
may  ||| S:1656 E:1660 ||| MD
be  ||| S:1660 E:1663 ||| VB
clinically  ||| S:1663 E:1674 ||| RB
useful  ||| S:1674 E:1681 ||| JJ
when  ||| S:1681 E:1686 ||| WRB
evaluating  ||| S:1686 E:1697 ||| VBG
the  ||| S:1697 E:1701 ||| DT
mass  ||| S:1701 E:1706 ||| NN
of  ||| S:1706 E:1709 ||| IN
the  ||| S:1709 E:1713 ||| DT
tumor ||| S:1713 E:1718 ||| NN
,  ||| S:1718 E:1720 ||| ,
whereas  ||| S:1720 E:1728 ||| IN
MMP-7  ||| S:1728 E:1734 ||| NNP
may  ||| S:1734 E:1738 ||| MD
be  ||| S:1738 E:1741 ||| VB
a  ||| S:1741 E:1743 ||| DT
prognostic  ||| S:1743 E:1754 ||| JJ
factor  ||| S:1754 E:1761 ||| NN
for  ||| S:1761 E:1765 ||| IN
DFS  ||| S:1765 E:1769 ||| NNP
in  ||| S:1769 E:1772 ||| IN
men  ||| S:1772 E:1776 ||| NNS
with  ||| S:1776 E:1781 ||| IN
rectal  ||| S:1781 E:1788 ||| JJ
cancer  ||| S:1788 E:1795 ||| NN
without  ||| S:1795 E:1803 ||| IN
distant  ||| S:1803 E:1811 ||| JJ
metastasis ||| S:1811 E:1821 ||| NN
.  ||| S:1821 E:1823 ||| .
